Skip To The Main Content
Important Announcement

PDA COVID-19 Updates/Podcast/Survey

PDA Statement Regarding COVID-19

Last updated: December 3, 2020

The coronavirus outbreak is a global concern, and our sympathies are with those who have been directly and indirectly impacted around the world.  At this point I believe that there are very few of us that have not sustained a loss related to COVID-19 whether it be a direct family member or friend.

During this challenging time PDA is committed to maintaining opportunities for volunteers and individuals from the pharmaceutical industry to meet and connect.  At this time the majority of our events and meeting have moved to virtual platforms.  For the in-person events that continue to be offered we have implemented a set of measures designed to protect participants and staff from potential risks related to COVID-19. This includes adherence to recommendations from health authorities, a close and regular monitoring of the current and global COVID-19 situation, and official travel restrictions and warnings.

For PDA staff, we have suspending all business travel, until further notice. Our Pandemic Preparedness Plan is in effect, and we began teleworking for the majority of U.S. and EU employees on March 16, 2020.  We will continue to monitor the situation and make other announcements, as necessary. 

Be assured that we will continue to operate and are dedicated to providing the services that our members have come to expect from PDA.

Richard Johnson
PDA President & CEO


PDA COVID-19 Task Force Podcast Series

by PDA COVID-19 Task Force

The PDA (Parenteral Drug Association) COVID-19 Task Force was established to assist the pharmaceutical industry as it works to meet the many challenges that COVID-19 has created within the industry. This podcast series is intended to share insights on topics of interest related to COVID-19.

Episode 3
With Adam Caruso; Callum Chapman and Tony Cundell, PhD.

Episode 2
With Crystal M. Booth, M.M. and Adam Caruso

Episode 1
With Adam Caruso; Tony Cundell, PhD. and Jim Polarine